Hartwig Steckel is a pharmacist and the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy), Christian Albrecht University of Kiel, Germany. He became a licensed pharmacist in 1995 and received a Ph.D. degree in pharmaceutical technology from the University of Kiel, Germany, in 1997. From 1997 to 1999, he was the Head of a Pharmaceutical Development Laboratory and Technical Project Leader at AstraZeneca in Wedel, Germany, with international project team responsibility. During 2000 to 2004, he was a research scientist at the University of Kiel, leading to the Habilitation and Venia Legendi degree in the field of pharmaceutical technology and biopharmaceutics. In 2006, Steckel stepped back to industry and accepted a position as the Head of Global Pharmaceutical Development at Intendis GmbH. Since October 2007, Steckel has been a Full Professor of pharmaceutics and biopharmaceutics at the University of Kiel and the Director of the Department of Pharmaceutics and Biopharmaceutics, Institute of Pharmacy. He has published more than 50 research articles and a great many of abstracts on the characterization of pharmaceutical aerosols, inhalation devices and formulation development of metered-dose inhalers, dry powder inhalers, and nebulizer solutions and suspensions, and he is a coinventor of several patents. His current research is focused on dosage forms for oral inhalation, with special focus on dry powder inhalation, formulation stabilization in CFC-free propellants, peptide/protein/nucleotide formulations for inhalation, and aqueous suspensions for pulmonary delivery. Other research interests and activities cover the production of pellets by extrusion/spheronization, hot melt extrusion, new delivery systems for topical, dermal and transdermal administration, and targeted delivery to inflamed mucosa.
Biography Updated on 20 April 2010